With the evolution of diabetes technology, those living with Type 1 diabetes are given a wider arsenal of tools with which to achieve glycaemic control and improve patient-reported outcomes. Furthermore, the use of these technologies may help reduce the risk of acute complications, such as severe hypoglycaemia and diabetic ketoacidosis, as well as longterm macro-and microvascular complications. In addition, diabetes technology can have a beneficial impact on psychosocial health by reducing the burden of diabetes. Unfortunately, diabetes goals are often unmet and people with Type 1 diabetes too frequently experience acute and long-term complications of this condition, in addition to often having less than ideal psychosocial outcomes. Increasing realization of the importance of patient-reported outcomes is leading to diabetes care delivery becoming more patient-centred. Diabetes technology in the form of medical devices, digital health and big data analytics have the potential to improve clinical care and psychosocial support, resulting in lower rates of acute and chronic complications, decreased burden of diabetes care, and improved quality of life.
Introduction

Diabetes complications
Based on the results of the Diabetes Complications and Control Trial, tight glycaemic control is necessary to minimize the risk of long-term microvascular and macrovascular complications, including retinopathy, nephropathy, neuropathy and cardiovascular disease [1] , in individuals with Type 1 diabetes mellitus. While the incidence of microvascular and macrovascular complications in the paediatric population remains low (Table 1) , longer diabetes duration and elevated HbA 1c concentrations while young increases future risk of complications in adulthood [2] . The American Diabetes Association (ADA) and the International Society for Pediatric and Adolescent Diabetes (ISPAD) recommend HbA 1c targets of <59 mmol/mol (7.5%) for people aged <18 years and <53 mmol/mol (7%) for people aged >18 years, while the National Institute of Health and Care Excellence (NICE) in the UK recommends an HbA 1c target of <48 mmol/mol (6.5%) [3] [4] [5] . Median HbA 1c differs among countries, and even among individual clinics within the same country, but the vast majority of these median HbA 1c values remain above prescribed glycaemic targets (Table 2) . Optimal diabetes management requires both the medical and psychosocial needs of individuals with Type 1 diabetes and their caregivers to be addressed.
Long-term complications
The current screening guidelines for microvascular complications from the ADA and ISPAD are shown in Table 3 [4, 5] . The risks of all forms of complications increase with higher HbA 1c concentration, increasing diabetes duration, hypertension, presence of other microvascular complications, obesity, insulin resistance, hyperlipidaemia and smoking [6] . Furthermore, the Diabetes Research in Children (DirecNet) study has shown that individuals with Type 1 diabetes have white matter differences in the brain and cognitive differences compared with individuals without Type 1 diabetes. These studies showed that the degree of structural differences in the brain were related to the degree of chronic hyperglycaemia, hypoglycaemia and glucose variability [7] .
Acute complications
In addition to long-term complications, people with Type 1 diabetes are also at risk of acute complications. Severe hypoglycaemia, a hypoglycaemic event resulting in altered/ loss of consciousness or seizures, is a serious complication of insulin therapy. If unnoticed and untreated, severe hypoglycaemia can result in death. Fortunately, the incidence of severe hypoglycaemia is low (Table 4) . A recent analysis of three diabetes registries showed that target HbA 1c can be achieved without an increase in the incidence of severe hypoglycaemia [8] , a contrast from historic Diabetes Control and Complications Trial data [9] .
The incidence of diabetic ketoacidosis, a life-threatening consequence of diabetes, remains unacceptably high in children with established diabetes (Table 5 ). The annual incidence of ketoacidosis was 5% in the Prospective Diabetes Follow-Up Registry (DPV) in Germany and Austria, 6.4% in the National Paediatric Diabetes Audit (NPDA), and 7.1% in the Type 1 Diabetes Exchange (T1DX) registry [10] . Psychosocial factors including female gender, non-white race, lower socio-economic status, and elevated HbA 1c all contribute to increased risk of diabetic ketoacidosis [11] .
Impact of patient-reported outcomes on diabetes complications
Psychosocial issues, such as psychiatric disorders, family stress and other factors, have an impact on diabetes selfmanagement behaviours and diabetes health outcomes. Psychiatric disorders, including eating disorders, are associated with worse diabetes self-management and higher HbA 1c , which can then increase risk of complications. Below, we outline some of the key patient-reported outcomes that have an impact on diabetes management and health outcomes [12, 13] .
Depression
Depression is more common in young people with Type 1 diabetes than in young people without a chronic disease; a recent study found that 13% of young people with Type 1 diabetes were experiencing symptoms of depression [14] . Depression can make it more difficult to engage in diabetes self-management behaviours, and as a result, contributes to suboptimal glycaemic control and lower rates of selfmonitoring of blood glucose (SMBG) in young people with Type 1 diabetes [15] .
Diabetes distress
Unlike depression, diabetes distress is not a clinical diagnosis but rather emotional distress that comes from the burden of living with and managing diabetes [16] . A recent systematic review found that roughly one-third of young people with Type 1 diabetes (age 10-20 years) have some level of diabetes distress and that diabetes distress was consistently associated with higher HbA 1c and worse self-management [17] . Parental diabetes distress can influence the child's diabetes management, resulting in a greater likelihood of having higher HbA 1c levels or more severe hypoglycaemia [18] .
Eating and weight
Eating and weight-related comorbidities also exist for individuals with Type 1 diabetes. There is a higher incidence of obesity in individuals with Type 1 diabetes on intensive insulin therapy. In the T1DX registry, 36% of participants were overweight or obese [19] . Women/girls and people of Hispanic/Latino ethnicity had the highest incidence of obesity. Adolescent girls and young adult women with Type 1 diabetes are more likely to omit insulin for weight loss and have disordered eating habits [20] . This same study found that girls who omitted insulin were more likely to have microvascular complications.
Health-related quality of life
In addition to screening for and treating depression and diabetes distress to improve overall diabetes management, it is equally important to assess quality of life as well as positive coping factors that may also influence self-management and well-being. For example, lower scores on the PROMIS â measure of global health, which assesses social relationships as well as physical and mental well-being, have been linked to higher depression scores and less frequent blood glucose checks [13] . Furthermore, coping strategies such as problemsolving, emotional expression, and acceptance have been linked to lower HbA 1c and enhanced quality of life [21] .
Current state of diabetes care
Current care for children and adolescents with Type 1 diabetes employs strategies to lower HbA 1c concentrations and increase the time blood glucose levels are in the target range, to prevent acute and chronic complications, and to optimize quality of life. To achieve these goals, there is a shift in diabetes care to become more patient-and caregivercentred. Patient-centred care involves diverse areas such as What's new?
• Diabetes technology presents the potential to make diabetes care more patient-centric, improve care, and reduce current and future complications of diabetes.
• Optimal diabetes management requires both the medical and psychosocial needs of people with Type 1 diabetes and their caregivers to be addressed. Diabetes technology will play an increasing role in the future of diabetes care.
• The aim of this paper was to demonstrate how, by incorporating technology into diabetes care, we can increase patient-centered care, reduce acute and chronic diabetes complications, and improve clinical outcomes and quality of life.
patient-initiated goal-setting, self-management skills, and patient-reported outcomes. Healthcare providers need to take psychosocial factors into account when working with young people with Type 1 diabetes, as psychosocial constraints, such as level of parental involvement, stigma, family conflict and others, may present barriers to achieving strict glycaemic targets [22] . However, having small, achievable goals that are identified by the person with Type 1 diabetes in conjunction with their caregiver(s) is empowering, with the net result of improving clinical outcomes and increasing engagement.
Technology has the potential to make diabetes care more patient-centred. Medical device technology, digital health and big data aim to decrease the burden of daily diabetes tasks and provide more personalized insights to improve clinical outcomes and quality of life. While this technology presents opportunities, the sheer volume of data may impose a burden on both patient and provider. The aim of the present review was to demonstrate how, by incorporating technology into diabetes care, we can increase patientcenteredness, reduce acute and chronic diabetes complications, and improve clinical outcomes and quality of life.
Role of technology in decreasing diabetes complications
Diabetes device technology Self-monitoring of blood glucose via multiple finger sticks for capillary blood samples per day has been the 'gold standard' for glucose monitoring, but SMBG only provides glucose measurements as snapshots in time. Still, the majority of young people with Type 1 diabetes use SMBG as their main method to assess glycaemia. Data from the T1DX registry suggest that an increased frequency of SMBG is associated with lower HbA 1c levels [23] . The development of continuous glucose monitoring (CGM) provides more values, along with the rate and direction of glucose changes. Among registries reporting CGM use (Table 2 ), the T1DX registry had the highest reported usage at 11% in 2015; however, usage was only 6.5% among young people (ages 2-25 years) [24] . Another type of CGM, the Abbott FreeStyle Libre (FlashCGM), has the benefit of being factory-calibrated, eliminating the need for finger sticks to calibrate, as is needed with other CGM devices [25] . Although the FlashCGM measures blood glucose continuously, it does not provide continuous blood glucose readings, but requires the user to scan and upload the data for viewing. CGM technology can play a role in improving glucose control and thereby improving diabetes outcomes and decreasing complications. With continued use, CGM has been shown to decrease the incidence of hypoglycaemia and HbA 1c levels [26] . CGM also has benefits for quality of life. In the recent DIAMOND study, a randomized controlled trial that tested CGM vs SMBG for adults with poorly controlled Type 1 diabetes ª 2018 Diabetes UK using multiple daily injections, the CGM group saw greater reductions in diabetes distress [27] . Insulin can be administered via multiple daily injections or continuous subcutaneous insulin infusion (insulin pumps).
Over the last 30 years, insulin pumps have become smaller with more features, making them a valuable alternative to multiple daily injections. Insulin pump use in various registries ranges from as low as 5.9% among paediatric [28] to as high as 74% in the German/Austrian DPV in children aged <6 years (Table 2 ) [29] . Recent data suggest that consistent use of insulin pumps can result in improved HbA 1c values and decreased incidence of severe hypoglycaemia [30, 31] . Insulin pumps have been associated with improved quality of life [32] . The data on insulin pumps and diabetic ketoacidosis are less clear. There may be a slight increase in ketoacidosis admissions in individuals receiving insulin pump therapy [33] , but recent studies suggest a decrease in the incidence of ketoacidosis with insulin pump use [24, 31] . The next step in diabetes device technology involves integration of CGM and insulin pump technologies (Table 6 ). When CGM and insulin pumps were used together as sensor-augmented pumps or closed-loop systems, there was further improvement in HbA 1c levels and incidence of severe hypoglycaemia [34, 35] . Sensor-augmented pump and closed-loop systems can also contribute to improvements in quality of life and other psychosocial outcomes. Studies have found improvements in health-related quality of life, treatment satisfaction and efficacy and reduced social burden [36] as a result of switching from injections and SMBG to sensoraugmented pumps. In addition to the Medtronic 670G system that was approved by the US Food and Drug Administration in 2016, there are several other hybrid closed-loop systems currently undergoing clinical trials with further innovations including mobile phone-based interfaces, factory-calibrated CGM devices, and glucagon integration. While hybrid closed-loop systems may appear to decrease burden compared with traditional methods of diabetes management, the additional steps required to use these systems may serve as barriers to care for individuals with diabetes, particularly adolescents and those in complex psychosocial situations. The future of artificial pancreas technology is the development of a fully closed-loop that does not require calibrations or meal announcements. These systems aim to maintain blood sugars within the target range, leading to a decrease in short-term complications, HbA 1c and, by extension, long-term complications. In addition to these metrics, closed-loop systems may improve health-related quality of life by reducing the mental and physical burdens of managing diabetes by automating some aspects of diabetes management and decreasing the number of invasive procedures [37] .
Digital health
Building self-management skills
The majority of Type 1 diabetes management is carried out outside the clinical setting and in individuals' daily lives. People with Type 1 diabetes must make complex treatment decisions multiple times daily; thus, diabetes self-management skills are central to optimal diabetes management. Unfortunately, many people with Type 1 diabetes and their caregivers are not sufficiently familiar with the necessary diabetes self-management skills. One study from the Netherlands suggests that adolescents with overall higher problem behaviour rates had higher HbA 1c levels (P = 0.029) and those with lower confidence in diabetes self-care also had higher HbA 1c levels (P< 0.01) [38] . Given the relative ineffectiveness of current methods of teaching diabetes self-management to children and adolescents, the current education model must evolve. Teaching of self-management skills is an iterative process. Parents are often the first who learn these skills. As children become older, they start receiving more independence over their diabetes care; however, the transition of responsibilities from caregiver to child is often unstructured and haphazard. It is important to ensure that both individuals with diabetes and their caregivers have adequate self-management skills throughout the diabetes journey.
In the developed world (nations with the highest gross domestic product), 87% of the population has access to the internet and 68% report using a smartphone [39] . Even in developing countries, 54% of people use the internet and 37% own smartphones [39] . In many areas, smartphones are the primary source of internet access and are readily available. Despite the rise in internet and mobile technology, diabetes education remains primarily face-to-face and in the form of written materials; however, people with diabetes and their caregivers are already turning to the internet for more information regarding diabetes care. As a result, more clinics, such as ours, are making educational materials available on clinic websites. There are >1000 apps for diabetes on the Apple App Store and the Google Play store. Many of these apps have focused on nutrition, blood glucose logging, and insulin dosing. Given the prevalence of smartphones and the interest in having diabetes apps handy, there is the potential for using a smartphone to deliver education and decision support tools. These tools can be personalized to meet an individual and family's goals. The challenge is developing a tool that will remain engaging. Having diabetes education available online or on a mobile app will allow patients and caregivers to access this information and expand their selfmanagement skills at a pace that suits their goals.
Using technology to assess psychosocial barriers to care
The new psychosocial position statement from the ADA recommends routine psychosocial screening in clinic. These recommendations include screening for: 1) depressive symptoms annually, at diagnosis, or with changes in medical status; 2) anxiety and worry about hypoglycaemia, complications and other diabetes-specific worries; 3) disordered eating and insulin omission for purposes of weight control; 4) and diabetes distress in children as young as 7 or 8 years old [16] . Implementation of in-clinic screening for depression in young people with Type 1 diabetes has already been shown to be feasible, acceptable and able to identify individuals in need of treatment who may otherwise have gone unnoticed for a longer period of time which would have been having a detrimental impact on physical health and quality of life [13, 40] . These programmes typically use tablets (e.g. Apple iPads) to administer surveys to streamline the screening process and automatically score measures [13, 40] . This automation allows psychologists and social workers to focus on care delivery rather than screening. In addition to depression screening, automated tablet-based screening for parental depression, distress and anxiety; problem-solving skills; and resilience/positive coping factors can help the care team understand other psychosocial barriers to care. This approach allows the development of patient-and caregiver-centred interventions to improve these barriers, thereby improving clinical outcomes and complication rates.
Telemedicine
Care Delivery. As Type 1 diabetes care is evolving to be more patient-centred, technology can play a key role in bringing diabetes care to the individual with diabetes. Many paediatric diabetes centres are in urban areas with high population density. Individuals with diabetes who live far from the nearest diabetes centre often miss school and their caregivers miss work to receive care, which can limit interaction with the diabetes care team. Telemedicine, which involves healthcare delivery via a video conferencing system, can deliver quality diabetes care to a young person with diabetes and their family while reducing travel and time lost from school and work. Studies have demonstrated that telemedicine can deliver similar quality of care to face-to face-visits [41] . This study examined the use of telemedicine to deliver care to another clinic site with the presence of a diabetes educator or nurse [41] . Some clinics, such as our site, have been delivering both clinic-to-clinic visits as well as clinic-to-home visits, with high levels of satisfaction from young people with diabetes, family, and providers (unpublished data).
In areas where endocrinologists are unable to deliver all diabetes care, even via telemedicine, local providers can be trained using telemedicine to expand access. One telemedicine model, Project Extension for Community Health Outcomes (ECHO), trains local primary care providers to deliver specialty care in underserved areas. This model is now expanding to include diabetes [42] . The Project ECHO model will allow individuals with diabetes to receive improved care closer to home.
Telemedicine can also be used for screening for diabetes complications. Individuals in low resource areas may not have access to an ophthalmologist for diabetic retinopathy screening. Several studies have shown that mobile technology CGM, continuous glucose monitoring.
ª 2018 Diabetes UK allows accurate telemedicine screening for diabetic retinopathy [43] . In addition, automated systems are being developed to accurately identify diabetic retinopathy in fundal images, which could preserve time for ophthalmologists to focus on treating diabetic eye disease rather than screening for diabetic eye disease [44] .
Health Coaching. Newer models of care that provide additional support, such as health coaches or case managers, and include family involvement have shown promise for improving health outcomes and lowering risk of hospitalization for young people with Type 1 diabetes [45] . Flexible Lifestyles Empowering Change (FLEX) is a behavioural intervention delivered by diabetes educators to adolescents struggling with diabetes using motivational interviewing and problemsolving skills to improve communication within the family and with care providers [46] . Novel Interventions in Children's Healthcare (NICH), developed at Oregon Health and Science University, takes into account an individual's family, school and other contexts to improve management of diabetes. NICH delivers intensive behavioural family systems therapy and case management and assists with care coordination and communication between family and healthcare providers, and results show that this intensive programme has reduced hospitalizations for diabetic ketoacidosis among young people with Type 1 diabetes with history of multiple hospitalizations and is cost-effective [45] . Interventions in the NICH programme combine both in-person and textmessaging. While health coaching interventions are traditionally delivered face-to-face, companies such as Livongo and WellDoc have developed models for successful diabetes health coaching in patients with Type 2 diabetes using telemedicine. These same models can be used to deliver telemedicine-based health coaching for adolescents with Type 1 diabetes. The Colorado Young Adults with Type 1 Diabetes (CoYoT1) Clinic offers peer support and virtual clinic visits. The pilot programme was found to be feasible, acceptable and time-saving for this age group (18-25 years) that is traditionally more challenging to engage in care [47] .
Big data analytics
Personalized care delivery
Big data consists of large datasets that can be computationally analysed to provide insights leading to improved outcomes. With the advent of electronic health records, registries and downloadable medical devices, people with Type 1 diabetes have troves of data that can be analysed to provide insights on an individual and population level. Big data analytics for diabetes are still in the early stages, but present great potential for improving diabetes care. IBM Watson Health has partnered with Medtronic to deliver personalized insights to individuals with diabetes based on device data [48] . Numerous other systems, such as the nonprofit Tidepool system (https://tidepool.org/), allow people with Type 1 diabetes to access their data, share their data with the healthcare team, and share de-identified data with the research community. Data analysis and insights such as this can form the basis for the delivery of personalized digital health coaching. For example, historical patterns can be analysed to predict activity and lead to pro-active insulin adjustment to prevent hypoglycaemia. Data aggregation is not only limited to diabetes devices. In the connected world, mobile phones can track location and activity. Other wearables, devices and apps can track information about sleep, heart rate, blood pressure, temperature and menstrual cycles, which can be used to personalize diabetes care.
Quality improvement
Quality improvement is a systematic and continuous approach to improve healthcare delivery and healthcare outcomes. Nations with universal healthcare systems, such as Sweden and the UK, maintain national registries to track patients, clinics and data on individuals with diabetes. Access to these data has allowed benchmarking at the clinic level and opening up of dialogue to share best practices. This has led to improved clinical outcomes [49] . In addition to national registries, several organizations such as the DPV, the SWEET Group, and the T1DX registry have all established quality improvement registries. Sweden has started including patient-reported outcomes in their national registry to improve qualitative aspects of diabetes care [50] . These registries allow benchmarking of data from many clinics across different countries with the goal of forming learning collaboratives to improve diabetes care. Given the digital nature of these registries, big data analytics are used to identify practices that have been successful at improving diabetes care and minimizing diabetes-related complications.
Conclusions
With the evolution of diabetes technology, Type 1 diabetes management in the 21 st century is becoming ever more patient-centred. Research has shown that taking care of both the medical and psychosocial needs of a child with Type 1 diabetes and the child's caregivers can improve clinical outcomes and thereby decrease acute and chronic complications. Technology will increasingly play a pivotal role in patient-centred diabetes care by improving clinical care, cultivating self-management skills, and allowing more frequent touch points with the diabetes care team.
Diabetes device technology
While a cure for Type 1 diabetes is still being investigated, artificial pancreas technology is quickly evolving. The first hybrid closed-loop system was commercially available this year with the ultimate goal of developing a fully automated insulin delivery system involving minimal human intervention. Studies have shown an improvement in glycaemic control while minimizing hypoglycaemia, which will translate into a decrease in the incidence of both acute and chronic complications. The Type 1 diabetes patient and caregiver community are strong advocates for bringing research findings rapidly into clinical practice. The development of artificial pancreas technology has even led to some caregivers of children with Type 1 diabetes to develop their own automated insulin delivery systems.
Digital health
Technology can also play a role in the improvement of diabetes self-management skills. With the move towards the patient being the centre of clinical care, education needs to be tailored to meet the needs of the patient and the family. Mobile apps and online modules can be used to deliver reinforcement of diabetes learning. In addition, telemedicine can be used to provide clinical care, diabetes education and psychosocial supports to people with Type 1 diabetes.
Promising models, such as FLEX and NICH, can be used to provide virtual health coaching to high-risk individuals with Type 1 diabetes through telemedicine and messaging. Psychology and social work support can be provided through telemedicine to improve patient-reported outcomes. Improvement of patient-reported outcomes and diabetes self-management skills have the potential to improve clinical outcomes, decrease complications and improve patient satisfaction.
Big data analytics
Diabetes registries and electronic health records contain large volumes of patient data that can be analysed to develop higher-quality care delivery. Improvements to diabetes care delivery can occur at both the population level and at the individual level using insights from big data analytics.
Technology in low resource settings
With increasing use of diabetes technology to improve Type 1 diabetes care and minimize complications, it is important that low resource areas are not left behind. Technology can play a role in bridging some of the resource gap between high resource and low resource areas. Big data analysis of diabetes registries and electronic health records can help identify lowcost, high-impact interventions that can be delivered in resource-poor areas. Telemedicine models, such as Project ECHO, can be used to train local providers to provide highquality diabetes care. Telemedicine can also be used to deliver diabetes care directly from endocrinologists to the patient.
Vision for the future of diabetes care
Technology will play a key role in delivering patient-centred care (Fig. 1 ). Telemedicine will allow diabetes care to go directly into the patient home, minimizing disruption for diabetes clinic visits and improving touch points with the care team. Personalized, ongoing education can be delivered through telemedicine, mobile apps and online modules. Highrisk patients will work closely with health coaches to improve self-management skills and problem-solving. Fully closed-loop systems will be used to minimize the burden of daily diabetesrelated tasks. As more data are available through diabetes registries and electronic health records, population level interventions can be developed to improve artificial pancreas systems and improve the quality of care. Big data analysis will also allow the development of more personalized diabetes treatment plans. Diabetes care will be a collaborative effort between the care team, patients and families. The clinical team, consisting of physicians, nurse practitioners, certified diabetes educators, nutritionists, social workers, psychologists and health coaches will work closely with families to achieve their goals. Care of the individual with Type 1 diabetes and their family involves not only treating glucose values but also improving patient-reported outcomes. Technology will be central to the delivery of this care model. By improving both clinical care and psychosocial supports, the future of diabetes care will lead to lower rates of acute and chronic complications, lower burden of care, and improve quality of life.
